P3781
Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium PreparationCetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate DaysReproductive Hormonal Alterations in ObesityGnRH Agonist and Antagonists in an Oocyte Donation ProgramThe Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte DonorsCetrotide Treatment OptimizationComparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVFCetrorelix and Ganirelix Flexible Protocol for (IVF)Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine FibroidsComparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary SuppressionFollitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)Frozen Embryo Transfer With GnRH-antagonist TrialEfficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor RespondersExtended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ETThe Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic PregnancyEstrogen, Diabetes, and Endothelial FunctionLive Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian ResponseComparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A
P4844
Q61915609-58B8CEB0-AE45-4AA2-BE31-C5C9D4EC2A8EQ61922929-12AA12EA-790E-4D82-96F0-BCB0BBA76214Q61955983-626D55FF-DD7A-4026-B79F-B5EBAD42BB25Q61965942-74F80F23-D659-47A9-A7E0-76EF4842EFF9Q61979958-1352C06E-51BE-41EE-984F-181C0D7A8AAEQ61980877-273AED91-09CA-432C-822F-3B221DDAFB10Q61981019-5D326BFB-4222-4E35-AA6D-96BD26C4113FQ62055016-59113241-1F29-49E4-ADD3-A21A91349994Q62812723-E97047F0-6F8C-416D-8773-D3D221E35165Q63062166-D9E32E8D-ACD0-40AD-B21B-3BA1EB0665DAQ63318884-E47C1DAF-988C-4612-A19F-E1DA8659000AQ63578650-74341C61-E1EA-4218-B3C0-73869C9D5458Q63587643-834B2A6D-A944-4AEE-8B89-ECA8A0E5742BQ63592614-C005DF51-E1A2-4AA8-BCC5-0BDF2A323065Q87076376-3B3E8B5B-598D-40F3-9B72-F37F706F01D2Q87932559-21DE0F13-8E04-451E-9106-2392BA5BCBA3Q96143342-0001E01F-3C85-4A5A-B701-8CC7938DC3A6Q96178994-9F0F5626-49D0-4F41-8279-E6306CC2FE97Q96178995-2AB1A1DB-122D-4F5F-831B-3C6610BB4FAF
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Cetroreliks
@pl
Cetroreliks
@sh
Cetroreliks
@sr
Cetrorelix
@it
Cetrorelix
@vi
cetrorelix
@en
سيتروريليكس
@ar
type
label
Cetroreliks
@pl
Cetroreliks
@sh
Cetroreliks
@sr
Cetrorelix
@it
Cetrorelix
@vi
cetrorelix
@en
سيتروريليكس
@ar
altLabel
Cetrorelix
@en
Cetrorelixum
@en
Cetrotide®
@en
SB-075
@en
prefLabel
Cetroreliks
@pl
Cetroreliks
@sh
Cetroreliks
@sr
Cetrorelix
@it
Cetrorelix
@vi
cetrorelix
@en
سيتروريليكس
@ar
P486
P592
P6366
P646
P661
P662
P665
P683
P1579
P2017
C[C@H](C(=O)N)NC(=O)[C@@H]1CCC ...... ](CC5=CC6=CC=CC=C6C=C5)NC(=O)C
P2067
1,429.669818